{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:08:11Z","timestamp":1785546491720,"version":"3.56.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.survophthal.2014.10.002","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T08:15:17Z","timestamp":1415175317000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The other CNVM: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents"],"prefix":"10.1016","volume":"60","author":[{"given":"Feisal A.","family":"Adatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2014.10.002_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5005\/jp-journals-10020-1006","article-title":"Bilateral regression of choroidal neovascularization associated with pathologic myopia following unilateral intravitreal bevacizumab injection","volume":"1","author":"Anantharaman","year":"2011","journal-title":"World J Retina Vit"},{"key":"10.1016\/j.survophthal.2014.10.002_bib2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjo.2007.130260","article-title":"Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results","volume":"92","author":"Arias","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia","volume":"91","author":"Avila","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajo.2004.05.074","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age of treatment","volume":"138","author":"Axer-Siegel","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2009.166025","article-title":"Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation","volume":"94","author":"Baba","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1034\/j.1600-0420.2002.800116.x","article-title":"Optical coherence tomography of choroidal neovascularization in high myopia","volume":"80","author":"Baba","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2014.10.002_bib7","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2013VIP report no. 3","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.exer.2008.11.011","article-title":"Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells","volume":"88","author":"Carneiro","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2014.10.002_bib10","first-page":"1300","article-title":"Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia","author":"Chan","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.2008.145797","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study","volume":"93","author":"Chan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib12","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/bjo.2005.074716","article-title":"Choroidal neovascularisation in pathological myopia: an update in management","volume":"89","author":"Chan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib14","first-page":"951","article-title":"Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration","volume":"126","author":"Chang","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","article-title":"Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia","volume":"29","author":"Cohen","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib17","series-title":"The Myopias: Basic Science and Clinical Management","first-page":"7","year":"1985"},{"key":"10.1016\/j.survophthal.2014.10.002_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","article-title":"Pigment epithelium-derived factor: a potent inhibitor of angiogenesis","volume":"285","author":"Dawson","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.survophthal.2014.10.002_bib19","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1167\/iovs.04-0260","article-title":"The changing prevalence of myopia in young adults: a 13-year series of population-based prevalence surveys","volume":"46","author":"Dayan","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2014.10.002_bib20","first-page":"1855","article-title":"Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects","volume":"42","author":"Delori","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2014.10.002_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ajo.2004.04.055","article-title":"Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia","volume":"138","author":"Ergun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib22","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/IAE.0b013e318134eecd","article-title":"Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits","volume":"27","author":"Gaudreault","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2014.10.002_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","article-title":"Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab\u2014a randomized controlled trial","volume":"149","author":"Gharbiya","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","article-title":"Choroidal neovascularization","volume":"137","author":"Grossniklaus","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006982-199212020-00009","article-title":"Pathologic findings in pathologic myopia","volume":"12","author":"Grossniklaus","year":"1992","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","article-title":"Visual prognosis of disciform degeneration in myopia","volume":"90","author":"Hampton","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00417-008-1021-2","article-title":"Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy","volume":"247","author":"Hayashi","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib31","first-page":"707","article-title":"Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia","volume":"27","author":"Hern\u00e1ndez-Rojas","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib32","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/IAE.0b013e31821800a4","article-title":"Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia","volume":"31","author":"Iacono","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","article-title":"Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"32","author":"Iacono","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","article-title":"Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization","volume":"149","author":"Ikuno","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib36","first-page":"721","article-title":"Choroidal neovascularization in degenerative myopia: Role of laser photocoagulation","volume":"18","author":"Jalkh","year":"1987","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.survophthal.2014.10.002_bib37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s00417-006-0324-4","article-title":"Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia","volume":"244","author":"Kojima","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00417-003-0803-9","article-title":"Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia","volume":"242","author":"Kojima","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-008-0995-0","article-title":"Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization","volume":"247","author":"Konstantinidis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib40","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/IAE.0b013e31821ba2dc","article-title":"Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization","volume":"31","author":"Kuo","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":"Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization","volume":"26","author":"Lai","year":"2012","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2014.10.002_bib42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/IAE.0b013e3181bcef24","article-title":"Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia","volume":"3","author":"Lalloum","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib43","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/01.iae.0000240121.28034.c3","article-title":"Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab","volume":"26","author":"Laud","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000101922","article-title":"Ocular photodynamic therapy\u2014standard applications and new indications (part 1). Review of the literature and personal experience","volume":"221","author":"Mennel","year":"2007","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2014.10.002_bib45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.opx.0000216019.88256.eb","article-title":"Vision loss in younger patients: a review of choroidal neovascularization","volume":"86","author":"Miller","year":"2006","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.survophthal.2014.10.002_bib46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/eye.2009.88","article-title":"Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results","volume":"23","author":"Mon\u00e9s","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2014.10.002_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bjo.87.2.173","article-title":"Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation","volume":"87","author":"Montero","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2014.10.002_bib49","series-title":"Estimated Statistics on Blindness and Vision Problems","first-page":"44","year":"1966"},{"key":"10.1016\/j.survophthal.2014.10.002_bib50","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/j.1442-9071.2011.02684.x","article-title":"Anti-vascular endothelial growth factor for myopic choroidal neovascularization","volume":"40","author":"Ng","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib51","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":"Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib52","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s003470050358","article-title":"Lipid metabolism in retinal pigment epithelium. Possible significance of lipoprotein receptors","volume":"95","author":"Noske","year":"1998","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.survophthal.2014.10.002_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archophthalmol.2009.408","article-title":"Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia","volume":"128","author":"Parodi","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/08820538.2011.559515","article-title":"Primary intravitreal ranibizumab for myopic choroidal neovascularisation","volume":"26","author":"Qureshi","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3129\/i08-104","article-title":"Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia","volume":"43","author":"Rh\u00e9aume","year":"2008","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib58","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/bjo.2009.173765","article-title":"Intravitreal anti-VEGF treatment in eye with combined choroidal neovascularization and vitreomacular traction syndrome","volume":"94","author":"Rotsos","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":"Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-010-1340-y","article-title":"Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome","volume":"248","author":"Ruiz-Moreno","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/oxfordjournals.epirev.a017924","article-title":"Epidemiology of myopia","volume":"18","author":"Saw","year":"1996","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.survophthal.2014.10.002_bib63","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0161-6420(13)31079-3","article-title":"Vascular targeting in photodynamic occlusion of subretinal vessels","volume":"101","author":"Schmidt-Erfurth","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/112067219700700401","article-title":"Long-term visual outcome of choroidal neovascularization in pathologic myopia: Natural history and laser treatment","volume":"7","author":"Secr\u00e9tan","year":"1997","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib65","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2005.081992","article-title":"Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study","volume":"90","author":"Shih","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib67","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IAE.0b013e31817eda41","article-title":"Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization","volume":"28","author":"Silva","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IAE.0b013e3181c9691e","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results","volume":"30","author":"Silva","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.survophthal.2007.12.004","article-title":"Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment","volume":"53","author":"Soubrane","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ajo.2006.01.085","article-title":"Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy","volume":"142","author":"Tatar","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.iae.0000254896.78766.74","article-title":"Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia","volume":"26","author":"Tewari","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib73","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12 month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib74","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial\u2013VIP report no. 1","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2014.10.002_bib75","first-page":"CD004765","article-title":"Laser photocoagulation for choroidal neovascularisation in pathologic myopia","author":"Virgili","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.survophthal.2014.10.002_bib76","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00417-009-1285-1","article-title":"Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?","volume":"248","author":"Voykov","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib77","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ajo.2009.05.026","article-title":"Intravitreal bevacizumab vs. sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia","volume":"148","author":"Wakabayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib78","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/IAE.0b013e3181f2a293","article-title":"Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia","volume":"31","author":"Wakabayashi","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib79","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib80","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/bjo.2007.135681","article-title":"Avastin in myopic choroidal neovascularisation: Is age the limit?","volume":"92","author":"Wong","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib81","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/eye.2008.404","article-title":"Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up","volume":"23","author":"Wu","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2014.10.002_bib82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2014.10.002_bib83","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/IAE.0b013e318227aa09","article-title":"Prognostic factors for visual outcome after intravitreal anti-vegf injection for na\u00efve myopic choroidal neovascularization","volume":"32","author":"Yoon","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib84","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/IAE.0b013e3181bd2fe4","article-title":"Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization","volume":"30","author":"Yoon","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2014.10.002_bib85","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0161-6420(01)01007-7","article-title":"Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups","volume":"109","author":"Yoshida","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib86","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2014.10.002_bib87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2011.04.014","article-title":"Comparing protein VEGF inhibitors: in\u00a0vitro biological studies","volume":"408","author":"Yu","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.survophthal.2014.10.002_biba","series-title":"Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization","year":"2013"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625714002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625714002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:41:37Z","timestamp":1758541297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625714002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0039625714002197"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2014.10.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The other CNVM: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2014.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}